Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US58933Y1055
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000BPD168
MRK
Merck & Co Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Drug Manufacturers—General · THEMEFOLIO: $TF-77
NAME
Merck & Co Inc
ISIN
US58933Y1055
TICKER
MRK
MIC
XNYS
REUTERS
MRK.N
BLOOMBERG
MRK US
Mo., 22.06.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderately to severe...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) to include children and adolescents aged 2 through 17 years who have completed a primary pediatric pneumococcal vacci...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 17.06.2026       Merck & Co.
US58933Y1055

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced results from a new global survey of dog owners and veterinarians revealing challenges and pain points associated with diagnosing the underlying cause of allergic skin disease in...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
So., 14.06.2026       Merck & Co.
US58933Y1055

Das Instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY wird ex Dividende/Zinsen gehandelt am 15.06.2026 The instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY has its ex-dividend/interest day on 15.06.2026...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph), Merck’s anti-PD-1 therapies, each in combination with WELIREG® (belzutifan), Merck’s first-in-class, oral hypoxi...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       Merck & Co.
US58933Y1055

Das Instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 12.06.2026 und ex Dividende/Zinsen am 15.06.2026 The instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY has its pre-dividend/interest day on 12.06.2026 and its ex-dividend/interest day on 15.06.2026...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       Merck & Co.
US58933Y1055

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 08.06.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy® (sacituzumab govitecan-hziy) in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, compared to KEYTRUDA...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 02.06.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference o...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 29.05.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the first-...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 28.05.2026       Merck & Co.
US58933Y1055

KIRKLAND, QC, May 28, 2026 /CNW/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, congratulates the Government of Ontario for its recent regulatory amendments under the Pharmacy Act, 1991 to expand the scope of practice for pharmacy professionals. This important policy change marks a shift toward more connected, convenient...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 10:30 a.m....
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 26.05.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the third quarter of 2026. Payment will be made on July 8, 2026, to shareholders of record at the close of business on June 15, 2026. About Mer...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 22.05.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), an antibody-d...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 18.05.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) being developed in collaboration with Kelun-Biotech, met its primary endpoints of overall survival (OS) and prog...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 12.05.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of cancer from the company’s comprehensive oncology portfolio and pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-June 2). The data reinfo...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoate, the company’s investigational oral PCSK9 inhibitor, using a tailored suite of enzymes in the latest issue of the peer reviewed journal Science. “Macrocyclic peptides have the...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 05.05.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). “The Terns acquisition reflects Merck’s continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to p...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Merck & Co.
US58933Y1055

Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2026. “We are moving with speed to transform our portfolio to one with a diversified set of growth drivers across a broad set of therapeutic areas,” said Robert M. Davis, chairman and...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional baseball players to launch the Playing with Heart educational program to help educate adults about the importance of knowing their low-density lipoprotein cholesterol (LDL-C), called...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 24.04.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Merck’s pending acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN) expired at 11:59 p.m., Eastern Time, on April 23,...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Merck & Co.
US58933Y1055

New collaboration taps Gemini Enterprise to realize business-driving value, innovation and patient impact across the next era of biopharmaceutical growthLAS VEGAS, April 22, 2026 /PRNewswire/ -- Cloud Next '26 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enha...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC). The trial evaluated the triplet therapy of KEYTRUDA® (pembrolizumab), Merck’s a...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck’s anti-PD-1 therapy, eac...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved ENFLONSIA™ (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants during their first RSV season. ENFLONSIA is contraindicated for i...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Merck & Co.
US58933Y1055

KIRKLAND, QC, April 15, 2026 /CNW/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, has released new data examining Canadians' knowledge of human papillomavirus (HPV) across age, gender, and regional groups. The survey revealed notable gaps in awareness--particularly among men and younger adults--even as rates of certain HP...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Merck & Co.
US58933Y1055

Daiichi Sankyo (TSE: 4568) and Merck’s, known as MSD outside of the United States and Canada, (NYSE: MRK) Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Merck & Co.
US58933Y1055

Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). On March 25, 2026, Merck announced that it had entered into a definitive agreement to acquire Terns. Up...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as Tiespectus, EYE201), a novel investigational bispecific antibody that directly activates Tie2 signaling and inhibits vascular endothelial growth factor (VEGF), for the treatment of...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in combination with paclitaxel, with or without bevacizumab, is approved in the European Union (EU) for the treatment of platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma in adults whose tumors expr...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 30. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists a...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced detailed results from CORALreef AddOn, an active comparator study designed to evaluate the efficacy and safety of enlicitide decanoate compared to other oral non-statin therapies (bempedoic acid, ezetimibe or bempedoic acid with ezetimibe) when added to backgr...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
So., 29.03.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced detailed results from the Phase 2 CADENCE study, which was designed to evaluate the efficacy, safety and tolerability of two doses (0.3 mg/kg and 0.7 mg/kg) of WINREVAIR™ (sotatercept-csrk) for the treatment of adults with the syndrome of combined post- and pr...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 25.03.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 24.03.2026       Merck & Co.
US58933Y1055

KIRKLAND, QC, March 24, 2026 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that British Columbia, Non-Insured Health Benefits (NIHB), Nova Scotia, Quebec and Veterans Affairs Canada (VAC) have added WINREVAIR® (sotatercept) to their public drug formularies. As the first jurisdictions to implement...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 18.03.2026       Merck & Co.
US58933Y1055

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), today announced the U.S. Food and Drug Administration (FDA) approved an expanded label for BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) in dogs. The updated indicatio...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it will present new clinical and real-world data reaffirming the long-term effectiveness of the company’s 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and its 4-valent HPV vaccine, GARDASIL® (Huma...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 16.03.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical data from the company’s cardio-pulmonary pipeline will be presented at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.26) in New Orleans, La., from March 28-30. The results shared will highlight Merck’s unwavering com...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
So., 15.03.2026       Merck & Co.
US58933Y1055

Das Instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY wird ex Dividende/Zinsen gehandelt am 16.03.2026 The instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY has its ex-dividend/interest day on 16.03.2026...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Merck & Co.
US58933Y1055

Das Instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 13.03.2026 und ex Dividende/Zinsen am 16.03.2026 The instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY has its pre-dividend/interest day on 13.03.2026 and its ex-dividend/interest day on 16.03.2026...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Sa., 28.02.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from the pivotal Phase 3 LITESPARK-022 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with WELIREG® (belzutifan), Merck’s first-in-class, oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibito...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Sa., 28.02.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA® (lenvatinib), an orally a...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 27.02.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly impro...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Fr., 27.02.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 25.02.2026       Merck & Co.
US58933Y1055

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the co...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mi., 25.02.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three pivotal Phase 3 trials evaluating the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg), (MK-8591A)] in adults with HIV-1. The findings were shared in late-breaking pre...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the TD Cowen 46th Annual Health Care Con...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink
Mo., 23.02.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its...
Zur Nachricht
Merck & Co.
Charts & Research Termsheets Terminal
Permalink